The radical scavenger IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate) decreases mortality, Enhances cognitive functions in water maze and reduces amyloid plaque burden in hAβPP transgenic mice

Journal of Alzheimer's Disease

Volumn 27, Issue 3, 2011, Pages 499-510

  Puoliväli, Jukka ^a   Nurmi, Antti ^a   Miettinen, Taina Kaisa ^a   Soleti, Antonio ^b   Riccardino, Francesca ^b   Kalesnykas, Giedrius ^a,c   Heikkinen, Taneli ^a   Vartiainen, Nina ^a   Pussinen, Raimo ^a   Tähtivaara, Leena ^a   Lehtimäki, Kimmo ^a   Yrjänheikki, Juha ^a   Canistro, Donatella ^d   Sapone, Andrea ^d   Spisni, Enzo ^d   Paolini, Moreno ^d  

^a Cerebricon Limited   (Finland)

^b Medestea Research   (Italy)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Alma Mater Studiorum   (Italy)

Author keywords

Alzheimer's disease; antioxidant; IAC (bis(1 hydroxy 2,2,6,6 tetramethyl 4 piperidinyl) decantionate); Tg2576 mice

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; BIS(1 HYDROXY 2,2,6,6 TETRAMETHYL 4 PIPERIDINYL) DECANTIONATE; RADICAL; SCAVENGER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MAZE TEST; MORTALITY; MOUSE; NERVE CELL CULTURE; NERVE FIBER GROWTH; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; SWIMMING; TRANSGENIC MOUSE; TREATMENT OUTCOME;

EID: 82555195147     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110881     Document Type: Article

References (39)

1. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR (2006) Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63, 38-46. (Pubitemid 43063860)
2. Zemlan FP, Thienhaus OJ, Bosmann HB (1989) Superoxide dismutase activity in Alzheimer's disease: Possible mechanism for paired helical filament formation. Brain Res 476, 160-162. (Pubitemid 19006378)
3. Pappolla MA, Omar RA, Kim KS, Robakis NK (1992) Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am J Pathol 140, 621-628.
4. Selley ML, Close DR, Stern SE (2002) The effect of increased concentrations of homocysteine on the concentration of (E)- 4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 23, 383-388. (Pubitemid 34312021)
5. Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptideassociated free radical oxidative stress. Free Radic Biol 32, 1050-1060. (Pubitemid 34603342)
6. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R (2006) Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397, 170-173.
7. Lovell MA, Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 85, 3036-3040. (Pubitemid 350057358)
8. Williams TI, Lynn BC, Markesbery WR, Lovell MA (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27, 1094-1099. (Pubitemid 43850642)
9. ReedTT, PierceWM,MarkesberyWR,ButterfieldDA(2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274, 66-76.
10. Praticò D, Sung S (2004) Lipid peroxidation and oxidative imbalance: Early functional events in Alzheimer's disease. J Alzheimers Dis 6, 171-175. (Pubitemid 38560253)
11. Eliuk SM, Renfrow MB, Shonsey EM, Barnes S, Kim H (2007) Active site modifications of the brain isoform of creatine kinase by 4-hydroxy-2-nonenal correlate with reduced enzyme activity: Mapping of modified sites by Fourier transform-ion cyclotron resonance mass spectrometry. Chem Res Toxicol 20, 1260-1268. (Pubitemid 47548294)
12. Sultana R, Perluigi M, Butterfield DA (2009) Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: Role of Abeta in pathogenesis. Acta Neuropathol 118, 131-150.
13. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273, 12817-12826. (Pubitemid 28246837)
14. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94, 9866-9868. (Pubitemid 27408156)
15. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52. (Pubitemid 28277534)
16. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF,Masters CL, Fairlie DP, Tanzi RE, Bush AI (1999) Cu(II) potentiation of Alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274, 37111-37116.
17. Adlard PA, Bica L, White AR, Nurjono M, Filiz G, Crouch PJ, Donnelly PS, Cappai R, Finkelstein DI, Bush AI (2011) Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One 6, e17669.
18. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D,Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H,Warden D,Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, MaierW, Jessen F, Ru¨ther E, Schu¨rmann B, Heun R,Ko¨lsch H, van den Bussche H, Heuser I,Kornhuber J,Wiltfang J, Dichgans M, Fro¨lich L, Hampel H, Gallacher J, Hu¨ll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mu¨hleisen TW, No¨then MM, Moebus S, Jo¨ckel KH, Klopp N, Wi mann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC; Alzheimer's Disease Neuroimaging Initiative, van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S; CHARGE consortium, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alpérovitch A, Lathrop M; EADI1 consortium, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjo¨rnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Boss'u P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43, 429-435.
19. VasinaV, Broccoli M, Ursino MG, Bellot SF, Soleti A, Paolini M, De Ponti F (2009) Effects of the non-peptidyl low molecular weight radical scavenger IAC in DNBS-induced colitis in rats. Eur J Pharmacol 614, 137-145.
20. D'Aleo V, Del Guerra S, Martano M, Bonamassa B, Canistro D, Soleti A, Valgimigli L, Paolini M, Filipponi F, Boggi U, Del Prato S, Lupi R (2009) The non-peptidyl low molecular weight radical scavenger IACprotects human pancreatic islets from lipotoxicity. Mol Cell Endocrinol 309, 63-66.
21. Canistro D, Affatato AA, Soleti A, Mollace V, Muscoli C, Sculco F, Sacco I, Visalli V, Bonamassa B, Martano M, Iannone M, Sapone A, Paolini M (2010) The novel radical scavenger IACis effective in preventing and protecting against post-ischemic brain damage in Mongolian gerbils. J Neurol Sci 290, 90-95.
22. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. (Pubitemid 26332733)
23. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
24. Valgimigli L, Pedulli GF, Paolini M (2001) Measurement of oxidative stress by EPR radical-probe technique. Free Radic Biol Med 31, 708-716. (Pubitemid 32835251)
25. Rak R, Chao DL, Pluta RM, Mitchell JB, Oldfield EH,Watson JC (2000) Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia. J Neurosurg 92, 646-651. (Pubitemid 30180671)
26. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F (2005) Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2, 22.
27. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, LevitesY,Verbeeck C, ZubairAC, Dickson D, Golde TE, Das P (2010) Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: Evidence against inflammation as a driving force for amyloid deposition. FASEB J 24, 548-559.
28. Dyrks T, Dyrks E, Hartmann T, Masters C, Beyreuther K (1992) Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 267, 18210-18217.
29. Varadarajan S, Yatin S, Aksenova M, Butterfield DA (2000) Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130, 184-208.
30. LimGP, Calon F, MoriharaT,Yang F,Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25, 3032-3040. (Pubitemid 40463537)
31. Hartman RE, Shah A, Fagan AM, Schwetye KE, Parsadanian M, Schulman RN, Finn MB, Holtzman DM (2006) Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis 24, 506-515. (Pubitemid 44716679)
32. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B,Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924, 133-140. (Pubitemid 34102301)
33. Flood JF, Morley JE, Roberts E (1991) Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer disease. Proc Natl Acad Sci U S A 88, 3363-3366. (Pubitemid 21916621)
34. Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Okamoto K, Shoji M (2000) Impaired neurotransmitter systems by Abeta amyloidosis in APPsw transgenic mice overexpressing amyloid beta protein precursor. Neurosci Lett 292, 155-158.
35. Conte V, Uryu K, Fujimoto S, Yao Y, Rokach J, Longhi L, Trojanowski JQ, Lee VM, McIntosh TK, Praticò DJ (2004) Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. Neurochem 90, 758-764. (Pubitemid 38989408)
36. Yang F, LimG.,BegumAN, Ubeda OJ, SimmonsMR,Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, ColeGM(2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280, 5892-5901.
37. Zhang C, Browne A, Child D, Tanzi RE (2010) Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 285, 28472-28480.
38. Ray B, Lahiri DK (2009) Neuroinflammation in Alzheimer's disease: Different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 9, 434-444.
39. Huesa G, Baltrons MA, G'omez-Ramos P, Morán A, Garćia A, Hidalgo J, Francés S, Santpere G, Ferrer I, Galea E (2010) Altered distribution of RhoA in Alzheimer's disease and AβPP overexpressing mice. J Alzheimers Dis 19, 37-56.